These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29650716)

  • 1. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.
    Jiang Y; Ni W
    Pharmacoeconomics; 2019 Jul; 37(7):943-952. PubMed ID: 30875022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis.
    Boettiger DC; Chattranukulchai P; Avihingsanon A; Chaiwarith R; Khusuwan S; Law MG; Ross J; Kiertiburanakul S
    PLoS One; 2021; 16(9):e0256926. PubMed ID: 34499685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA.
    Mortensen MB; Falk E; Li D; Nasir K; Blaha MJ; Sandfort V; Rodriguez CJ; Ouyang P; Budoff M
    JACC Cardiovasc Imaging; 2018 Feb; 11(2 Pt 1):221-230. PubMed ID: 28624395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
    Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
    J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
    Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States.
    Mitchell AP; Simpson RJ
    BMC Res Notes; 2012 Jul; 5():373. PubMed ID: 22828389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals.
    Spahillari A; Zhu J; Ferket BS; Hunink MGM; Carr JJ; Terry JG; Nelson C; Mwasongwe S; Mentz RJ; O'Brien EC; Correa A; Shah RV; Murthy VL; Pandya A
    JAMA Cardiol; 2020 Aug; 5(8):871-880. PubMed ID: 32401264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis.
    Hong JC; Blankstein R; Shaw LJ; Padula WV; Arrieta A; Fialkow JA; Blumenthal RS; Blaha MJ; Krumholz HM; Nasir K
    JACC Cardiovasc Imaging; 2017 Aug; 10(8):938-952. PubMed ID: 28797417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.
    Pletcher MJ; Pignone M; Earnshaw S; McDade C; Phillips KA; Auer R; Zablotska L; Greenland P
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):276-84. PubMed ID: 24619318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis.
    Boettiger DC; Newall AT; Chattranukulchai P; Chaiwarith R; Khusuwan S; Avihingsanon A; Phillips A; Bendavid E; Law MG; Kahn JG; Ross J; Bautista-Arredondo S; Kiertiburanakul S
    J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25494. PubMed ID: 32562359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study.
    Garcia-Gil M; Comas-Cufí M; Blanch J; Martí R; Ponjoan A; Alves-Cabratosa L; Petersen I; Marrugat J; Elosua R; Grau M; Ramos R
    Clin Pharmacol Ther; 2018 Oct; 104(4):719-732. PubMed ID: 29194590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.